VivoSeq
Cardiovascular

Venous Malformation

19

Pipeline Programs↗

6

Active Trials↗

13

Companies Involved↗

Venous malformation is an emerging landscape with 19 programs across 13 companies. The most active players are Roche, Prism Pharmaceuticals, Novartis. 3 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

6/100

Mech. Concentration

11/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 2P

Prism Pharmaceuticals

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 2S

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

90%

Small molecule

19 of 21 classified programs — the dominant modality here.

10%ALL OTHERSMonoclonal antibody210%

Small molecule leads; the ring shows all 21 classified programs, each share of the total. Modality classified for 100% of 21 pipeline programs.

Analysis

Trial Status

19

clinical trials

Unknown status9 · 47%
Completed4 · 21%
Recruiting4 · 21%
Not yet recruiting2 · 11%

Clinical Trials

Trial Activity

19 trials

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
Recruiting·PPalvella Therapeutics, Inc.·Phase 2·NCT06653842·15 enrolled
A Study of Enalapril in Treatment of Venous Malformations
Recruiting·OOslo University Hospital·Phase 2·NCT06788314·12 enrolled
An Exploratory Study to Evaluate the Efficacy and Safety of FCN-159 in Patients With Brain Arteriovenous Malformations
Recruiting·XXuanwu Hospital, Beijing·Phase 2·NCT06913725·10 enrolled
Treatment of Low-flow Venous Malformations With Electrosclerotherapy. Prospective Observational Study
Recruiting·—·N/A·NCT06189092·65 enrolled
A Study of Direct Oral Anticoagulants in Patients with Painful Venous Malformations with Localized Intravascular Coagulation
Not yet recruiting·OOslo University Hospital·Phase 2·NCT06729034·20 enrolled
In Situ Injection of Anti-angiogenics in Patients With Brain Arteriovenous Malformations Not Eligible for Exclusion Treatment
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 1·NCT07075757·20 enrolled
Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.
Completed·OOrfagen·Phase 2·NCT00462462·32 enrolled
Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)
Completed·UUniversity of Arkansas·Phase 2·NCT05125471·3 enrolled
Bevacizumab Therapy for Brain Arteriovenous Malformation
Completed·UUniversity of California, San Francisco·Phase 1·NCT02314377·2 enrolled
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
Completed·—·Phase 2·NCT00389935·14 enrolled
Observation vs Progesterone Treatment for Management of Uterine Arteriovenous Malformation
Unknown status·HHaEmek Medical Center, Israel·Phase 4·NCT05491343·28 enrolled
Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations
Unknown status·—·Phase 2·NCT02042326·50 enrolled
Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2
Unknown status·—·N/A·NCT03306836·408 enrolled
Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations
Unknown status·OOslo University Hospital·Phase 4·NCT01347294·135 enrolled
Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation
Unknown status·SStanford University·Phase 2·NCT04258046·30 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)